← All organizations
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2005First marketed drug
Dec 11, 2017First NDA
Dec 11, 2017Last known activity
Jul 23, 2024
Timeline
1950s
- Jul 1, 1959
Ferrer Internacional S.A.— Founded
2010s
- Dec 11, 2017
ozenoxacin— NDA Organization
- Dec 11, 2017
ozenoxacin— NDA Secondary Org
Drugs by trial phase (18 distinct, 23 trials)
Phase 4 (5 own, 0 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Candidiasis
- Candidiasis, Vulvovaginal
- Carcinoma
- Carcinoma, Squamous Cell
- Cardiovascular Diseases
- Cerebral Infarction
- Dermatomycoses
- Diarrhea
- Fibrosis
- Heart Failure
- Hot Flashes
- Hypertension
- Impetigo
- Infarction
- Myocardial Infarction
- Neoplasm Metastasis
- Spinal Cord Injuries
- Squamous Cell Carcinoma of Head and Neck
- Stroke
- Wounds and Injuries
Marketed drugs (1)
Recent trials (23)
- NCT05572996Lead sponsorN/A—
- NCT06355531Lead sponsorPhase 2Jul 23, 2024
- NCT05866926Lead sponsorPhase 3Mar 6, 2023
- NCT05178810Lead sponsorPhase 3Oct 18, 2021
- NCT04065529Lead sponsorPhase 3Aug 26, 2019
- NCT02917291Lead sponsorPhase 1/Phase 2Dec 1, 2016
- NCT02596126CollaboratorPhase 3Jul 1, 2016
- NCT02791958Lead sponsorPhase 2Mar 1, 2016
- NCT02715596CollaboratorPhase 3Dec 1, 2015
- NCT02090764Lead sponsorPhase 3Jun 1, 2014
- NCT02195609CollaboratorPhase 4Mar 1, 2014
- NCT01397461Lead sponsorPhase 3Mar 1, 2012
- NCT01549158Lead sponsorPhase 4Feb 1, 2012
- NCT01321255CollaboratorPhase 3Jan 1, 2012
- NCT01362218Lead sponsorPhase 2Oct 1, 2010
Details
- Founded
- Barcelona, ES Jul 1, 1959
- First NDA
- Dec 11, 2017
- Last known activity
- Jul 23, 2024